Crescent Biopharma, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CBIO research report →
Companycrescentbiopharma.com
Crescent Biopharma, Inc. , a biotechnology company, researches and develops cancer therapy candidates. Its pipeline includes CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
- CEO
- Joshua T. Brumm
- IPO
- 2014
- Employees
- 41
- HQ
- Waltham, MA, US
Price Chart
Valuation
- Market Cap
- $521.38M
- P/E
- -3.55
- P/S
- 43.88
- P/B
- 3.13
- EV/EBITDA
- -2.10
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 100.00%
- Op Margin
- -1372.85%
- Net Margin
- -1363.94%
- ROE
- -100.86%
- ROIC
- -88.00%
Growth & Income
- Revenue
- $10.84M · 0.00%
- Net Income
- $-153,942,000 · -217.25%
- EPS
- $-14.78 · -955.71%
- Op Income
- $-152,632,000
- FCF YoY
- -132.90%
Performance & Tape
- 52W High
- $27.41
- 52W Low
- $8.72
- 50D MA
- $17.79
- 200D MA
- $13.72
- Beta
- 1.20
- Avg Volume
- 249.87K
Get TickerSpark's AI analysis on CBIO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 15, 25 | Pinkas Jan | other | 70,025 |
| Dec 15, 25 | Pinkas Jan | other | 5,000 |
| Dec 15, 25 | Pinkas Jan | other | 17,507 |
| Dec 15, 25 | Doughty Christopher Grant | other | 8,000 |
| Dec 15, 25 | Doughty Christopher Grant | other | 58,855 |
| Dec 15, 25 | Doughty Christopher Grant | other | 14,714 |
| Dec 15, 25 | Brumm Joshua T | other | 10,000 |
| Dec 15, 25 | Brumm Joshua T | other | 45,117 |
| Dec 15, 25 | Brumm Joshua T | other | 180,467 |
| Dec 15, 25 | Scalzo Richard William | other | 57,688 |
Our CBIO Coverage
We haven't published any research on CBIO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate CBIO Report →